Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?

Progress in Cardiovascular Diseases

Volumn 59, Issue 3, 2016, Pages 253-261

  Bavishi, Chirag ^a   Bangalore, Sripal ^b   Messerli, Franz H ^c  

^a Mount Sinai St Luke's and Mount Sinai West Hospitals   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blocker; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; RAMIPRIL; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; TELMISARTAN; VALSARTAN;

ACUTE KIDNEY FAILURE; AGE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMBINATION DRUG THERAPY; COUGHING; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MORBIDITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; BLOOD PRESSURE; DRUG EFFECTS; PHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 85004143373     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.10.002     Document Type: Review

References (65)

1. 1. Bromfield, S., Muntner, P., High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep 15:3 (2013), 134–136.
2. 2. World Health Organization, A global brief on hypertension: silent killer, global public health crisis. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/, 2013 [Accessed on April 21, 2016].
3. 3. Bian, B., Kelton, C.M., Guo, J.J., Wigle, P.R., ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008. J Manag Care Pharm 16:9 (2010), 671–679.
4. 4. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:3 (2000), 145–153.
5. 5. Group PC, Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:9287 (2001), 1033–1041.
6. 6. Pitt, B., O'Neill, B., Feldman, R., et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87:9 (2001), 1058–1063.
7. 7. Nissen, S.E., Tuzcu, E.M., Libby, P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292:18 (2004), 2217–2225.
8. 8. Carey, R.M., Siragy, H.M., Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24:3 (2003), 261–271.
9. 9. Messerli, F.H., Nussberger, J., Vasopeptidase inhibition and angio-oedema. Lancet 356:9230 (2000), 608–609.
10. 10. The SOLVD Investigators, (eds.) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 325(5), 1991, 293–302.
11. 11. Kober, L., Torp-Pedersen, C., Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 76:1 (1995), 1–5.
12. 12. Bulpitt, C.J., Beckett, N.S., Cooke, J., et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 21:12 (2003), 2409–2417.
13. 13. Hansson, L., Lindholm, L.H., Niskanen, L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:9153 (1999), 611–616.
14. 14. Officers A, Coordinators for the ACRGTA, Lipid-lowering treatment to prevent heart Attack T. major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:23 (2002), 2981–2997.
15. 15. van Vark, L.C., Bertrand, M., Akkerhuis, K.M., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 33:16 (2012), 2088–2097.
16. 16. Dahlof, B., Sever, P.S., Poulter, N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:9489 (2005), 895–906.
17. 17. Patel, A., Group AC, MacMahon, S., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:9590 (2007), 829–840.
18. 18. Beckett, N.S., Peters, R., Fletcher, A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:18 (2008), 1887–1898.
19. 19. Lithell, H., Hansson, L., Skoog, I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21:5 (2003), 875–886.
20. 20. Yusuf, S., Diener, H.C., Sacco, R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:12 (2008), 1225–1237.
21. 21. Group NS, McMurray, J.J., Holman, R.R., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:16 (2010), 1477–1490.
22. 22. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:9311 (2002), 995–1003.
23. 23. Carlberg, B., Samuelsson, O., Lindholm, L.H., Atenolol in hypertension: is it a wise choice?. Lancet 364:9446 (2004), 1684–1689.
24. 24. Julius, S., Kjeldsen, S.E., Weber, M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:9426 (2004), 2022–2031.
25. 25. Bangalore, S., Kumar, S., Wetterslev, J., Messerli, F.H., Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ, 342, 2011, d2234.
26. 26. Chen, Y., Meng, L., Shao, H., Yu, F., Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertens Res 36:3 (2013), 252–261.
27. 27. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J., Hollenberg, N.K., Investigators AS, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:23 (2008), 2433–2446.
28. 28. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:23 (2012), 2204–2213.
29. 29. Nicholls, S.J., Bakris, G.L., Kastelein, J.J., et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310:11 (2013), 1135–1144.
30. 30. Nussberger, J., Wuerzner, G., Jensen, C., Brunner, H.R., Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39:1 (2002), E1–E8.
31. 31. Matchar, D.B., McCrory, D.C., Orlando, L.A., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:1 (2008), 16–29.
32. 32. Barnett, A.H., Bain, S.C., Bouter, P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:19 (2004), 1952–1961.
33. 33. Investigators O, Yusuf, S., Teo, K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:15 (2008), 1547–1559.
34. 34. Bangalore, S., Fakheri, R., Toklu, B., Ogedegbe, G., Weintraub, H., Messerli, F.H., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 91:1 (2016), 51–60.
35. 35. Azizi, M., Linhart, A., Alexander, J., et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18:8 (2000), 1139–1147.
36. 36. Izzo, J.L. Jr., Weinberg, M.S., Hainer, J.W., Kerkering, J., Tou, C.K., Amaze. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 6:9 (2004), 485–493.
37. 37. Doulton, T.W., He, F.J., MacGregor, G.A., Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:5 (2005), 880–886.
38. 38. Messerli, F.H., Staessen, J.A., Zannad, F., Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J 31:18 (2010), 2205–2208.
39. 39. Makani, H., Bangalore, S., Desouza, K.A., Shah, A., Messerli, F.H., Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, 346, 2013, f360.
40. 40. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:9638 (2008), 547–553.
41. 41. Diaz, K.M., Tanner, R.M., Falzon, L., et al. Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension 64:5 (2014), 965–982.
42. 42. Stevens, S.L., Wood, S., Koshiaris, C., et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ, 354, 2016, i4098.
43. 43. Mancia, G., Short- and long-term blood pressure variability: present and future. Hypertension 60:2 (2012), 512–517.
44. 44. Wang, J.G., Yan, P., Jeffers, B.W., Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens 8:5 (2014), 340–349.
45. 45. Zhang, Y., Agnoletti, D., Safar, M.E., Blacher, J., Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 58:2 (2011), 155–160.
46. 46. American Diabetes Association, http://www.diabetes.org/diabetes-basics/statistics/?referrer [Accessed May 24, 2016].
47. 47. American Diabetes A, Standards of medical care in diabetes – 2014. Diabetes Care 37:Suppl. 1 (2014), S14–S80.
48. 48. Chamberlain, J.J., Rhinehart, A.S., Shaefer, C.F. Jr., Neuman, A., Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 164:8 (2016), 542–552.
49. 49. Weber, M.A., Schiffrin, E.L., White, W.B., et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 32:1 (2014), 3–15.
50. 50. Ruilope, L.M., Solini, A., RAS blockade for every diabetic patient: pro and con. Diabetes Care 34:Suppl. 2 (2011), S320–S324.
51. 51. Bangalore, S., Fakheri, R., Toklu, B., Messerli, F.H., Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, 352, 2016, i438.
52. 52. Casas, J.P., Chua, W., Loukogeorgakis, S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:9502 (2005), 2026–2033.
53. 53. Lash, J.P., Go, A.S., Appel, L.J., et al. Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 4:8 (2009), 1302–1311.
54. 54. Mancia, G., Fagard, R., Narkiewicz, K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:28 (2013), 2159–2219.
55. 55. NKF/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Guideline 11: use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in CKD. http://www2.kidney.org/professionals/KDOQI/guidelines_bp/guide_11.htm [Accessed May 24, 2016].
56. 56. Kunz, R., Friedrich, C., Wolbers, M., Mann, J.F., Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:1 (2008), 30–48.
57. 57. Xie, X., Liu, Y., Perkovic, V., et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67:5 (2016), 728–741.
58. 58. Rahman, M., Pressel, S., Davis, B.R., et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 144:3 (2006), 172–180.
59. 59. Wing, L.M., Reid, C.M., Ryan, P., et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:7 (2003), 583–592.
60. 60. Hansson, L., Lindholm, L.H., Ekbom, T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:9192 (1999), 1751–1756.
61. 61. Bavishi, C., Ahmed, M., Trivedi, V., et al. Meta-analysis of randomized trials on the efficacy and safety of angiotensin-converting enzyme inhibitors in patients ≥65 years of age. Am J Cardiol, 2016 [in press].
62. 62. Furberg, C.D., Pitt, B., Are all angiotensin-converting enzyme inhibitors interchangeable?. J Am Coll Cardiol 37:5 (2001), 1456–1460.
63. 63. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:11 (2014), 993–1004.
64. 64. Bavishi, C., Messerli, F.H., Kadosh, B., Ruilope, L.M., Kario, K., Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J 36:30 (2015), 1967–1973.
65. 65. Unger, T., Paulis, L., Sica, D.A., Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 32:22 (2011), 2739–2747.